您当前所在的位置:首页 > 产品中心 > 产品信息
GSK4112_分子结构_CAS_)
点击图片或这里关闭

GSK4112

产品号 G0673 公司名称 Sigma Aldrich
CAS号 公司网站 http://www.sigmaaldrich.com
分子式 C18H21ClN2O4S 电 话 1-800-521-8956
分子量 396.88834 传 真
纯 度 ≥98% (HPLC) 电子邮件
保 存 Chembase数据库ID: 154578

产品价格信息

请登录

产品别名

标题
GSK4112
IUPAC标准名
tert-butyl 2-{[(4-chlorophenyl)methyl][(5-nitrothiophen-2-yl)methyl]amino}acetate
IUPAC传统名
tert-butyl 2-{[(4-chlorophenyl)methyl][(5-nitrothiophen-2-yl)methyl]amino}acetate
别名
1,1-Dimethylethyl N-[(4-chlorophenyl)methyl]-N-[(5-nitro-2-thienyl)methyl])glycinate
SR6452

产品登记号

MDL号 MFCD12912412

产品性质

Empirical Formula (Hill Notation) C18H21ClN2O4S
纯度 ≥98% (HPLC)
外观 off-white to tan powder
溶解度 DMSO: >20 mg/mL
GHS危险品标识 GHS05
GHS危险品标识 GHS08
GHS警示词 Danger
GHS危险声明 H318-H334
欧盟危险性物质标志 刺激性(Irritant) 刺激性(Irritant) (Xi)
MSDS下载 下载链接
GHS警示性声明 P261-P280-P305 + P351 + P338-P342 + P311
危险公开号 41-43
安全公开号 26-36/37/39
保存温度 2-8°C
德国WGK号 1

产品详细信息

详细说明 (English)
Biochem/physiol Actions
GSK4112 is a rev-erbα, (orphan nuclear receptor NR1D1) agonist, the first agent able to reset the circadian clock in a phase-dependent manner. Rev-erbα impacts the precision of the circadian clock by repressing target gene activities with the help of a nuclear receptor co-repressor complex (NCoR) and HDAC3. GSK4112 competes with heme (rev-erb′s natural ligand) and enhances co-repressor complex recruitment and thus, repression of transcription. suggests that pharmacological modulation through Rev-erb may provide new routes to treat metabolic diseases, especially disorders of adipogenesis regulated by rev-erba.1
详细说明 (简体中文)
Biochem/physiol Actions
GSK4112 is a rev-erbα, (orphan nuclear receptor NR1D1) agonist, the first agent able to reset the circadian clock in a phase-dependent manner. Rev-erbα impacts the precision of the circadian clock by repressing target gene activities with the help of a nuclear receptor co-repressor complex (NCoR) and HDAC3. GSK4112 competes with heme (rev-erb′s natural ligand) and enhances co-repressor complex recruitment and thus, repression of transcription. suggests that pharmacological modulation through Rev-erb may provide new routes to treat metabolic diseases, especially disorders of adipogenesis regulated by rev-erba.1

参考文献